Cellistic Unveils New Induced Pluripotent Stem Cell Manufacturing Platforms for Cancer and Regenerative Therapies

Key findings

• Cellistic has launched three iPSC-derived GMP manufacturing platforms: Echo-T, Echo-Cardio, and Echo-Endothelial.
• The platforms expand Cellistic’s existing Echo-NK offering beyond NK cells into T cells, cardiomyocytes, and endothelial cells.
• Cellistic says the goal is more scalable, standardized manufacturing for off-the-shelf allogeneic iPSC-derived cell therapies.

Cellistic has added three new induced pluripotent stem cell (iPSC) derived GMP manufacturing platforms to its lineup: Echo™-T, Echo™-Cardio, and Echo™-Endothelial, which serve as expansions to its Cellistic Echo™ portfolio for iPSC-derived allogeneic (donor-derived) cell therapies. 

Why it matters
As cell therapies move from clinical studies to commercialization, the industry is grappling with a manufacturing and scalability bottleneck. 

To help mitigate this issue, Cellistic has expanded its iPSC-derived natural killer (NK) cell manufacturing platform, Echo™-NK to scale other indications.

New platform rundown
They’ve expanded with three new iPSC offerings:

• Echo™-T: For iPSC-derived αβ T cells or regulatory T cells (Tregs, immune cells that can suppress immune responses). 
• Echo™-Cardio: For iPSC-derived cardiomyocytes (heart muscle cells). The company says these cells have a defined, homogeneous phenotype and are functionally relevant to cardiac regenerative programs.
• Echo™-Endothelial: For iPSC-derived endothelial cells (cells that line blood vessels). Cellistic says these cells are intended for work in vascular biology, inflammation, and the tumor microenvironment.

Cellistic notes that its lab is an EMA-certified GMP facility in Belgium, and it is FDA- and PMDA-compliant. (EMA and PMDA are the European and Japanese equivalents of the FDA). 

The new platforms add to its Pulse™ cell line development and Echo™ manufacturing platforms, providing, it says, a turnkey path from gene-edited iPSCs to fully characterized, GMP-compliant cell therapy products across a broader range of cell types. The company also has developed a proprietary gene-editing platform for the cells, called STAR-CRISPR™.

Cellistic says the platforms are already being used in multiple active development programs, some of which are approaching IND submission.

Want to keep up on regenerative medicine? Get the weekly newsletter here.

Similar stories

Encellin and Breakthrough T1D Planning Phase 1 of Immune-Protected Cell Therapy for Type 1 DiabetesSep 23, 2026Webinar: Scaling iPSC Therapies Without Scaling VariabilityOn-DemandAspen Neuroscience Publishes Preclinical Data on Parkinson’s iPSC-Derived Cell TherapySep 21, 2026Made Scientific Acquires Resilience’s 85K-Square-Foot Cell Therapy FacilitySep 21, 2026

Editor’s Picks

Century Therapeutics Reports Sustained Glucose Control With iPSC-Derived Islets in Diabetic Mice, IND SoonOct 20, 2026Umbilical Cord Mesenchymal Stem Cell Injections Lower Pain Scores More Than Hyaluronate in 50-Patient Severe Knee Osteoarthritis TrialOct 18, 2026Stempeutics Nabs US Patent for Osteoarthritis Treatment Combining Bone Marrow Stem Cells and Hyaluronic AcidOct 18, 2026Novadip Secures €10.4M for Pivotal Phase 3 Bone Repair Cell Therapy TrialSep 21, 2026